Shots:

• Regeneron will be responsible to deliver treatment doses for six years post-approval of product from the FDA- will receive compensation of ~$10M & average of $67M/year in 2021 and each for the next five years (2022-2026) respectively
• In 2019- the PALM trial evaluated REGN-EB3 vs ZMapp conducted in the Democratic Republic of the Congo- was stopped as the REGN-EB3 crossed the pre-specified superiority threshold for preventing death in Ebola patients
• Regeneron's REGN-EB3 is a novel anti-viral Ab cocktail developed using its VelociSuite platform in collaboration and funding provided by BARDA. The product is under priority review by the US FDA with PDUFA date Oct 25- 2020

Ref: BusinessWire | Image: Behnace